Literature DB >> 10980602

A ribonucleotide reductase gene is a transcriptional target of p53 and p73.

K Nakano1, E Bálint, M Ashcroft, K H Vousden.   

Abstract

Many p53-inducible genes have been identified that might play a role in mediating the various downstream activities of p53. We have identified a close relative of ribonucleotide reductase, recently named p53R2, as a p53-inducible gene, and show that this gene is activated by several stress signals that activate a p53 response, including DNA damaging agents and p14(ARF). p53R2 expression was induced by p53 mutants that are defective for the activation of apoptosis, but retain cell cycle arrest function, although no induction of p53R2 was seen in response to p21(WAF1/CIP1)-mediated cell cycle arrest. Several isoforms of the p53 family member p73 were also shown to induce p53R2 expression. Transient ectopic expression of either wild type p53R2 or p53R2 targeted to the nucleus, did not significantly alter cell cycle progression in unstressed cells. The identification of this gene as a p53 target supports a direct role for p53 in DNA repair, in addition to inhibition of growth of damaged cells. Oncogene (2000) 19, 4283 - 4289

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980602     DOI: 10.1038/sj.onc.1203774

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  75 in total

1.  BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets.

Authors:  Timothy K MacLachlan; Rishu Takimoto; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

2.  On model ensemble analyses of nonmonotonic data.

Authors:  Tomas Radivoyevitch; Charles A Kunos
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2012       Impact factor: 1.381

3.  Reprimo 824 G>C and p53R2 4696 C>G single nucleotide polymorphisms and colorectal cancer: a case-control disease association study.

Authors:  William D Beasley; John Beynon; Gareth J S Jenkins; Jim M Parry
Journal:  Int J Colorectal Dis       Date:  2008-04       Impact factor: 2.571

4.  Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.

Authors:  Xiyong Liu; Lily Lai; Xiaochen Wang; Lijun Xue; Sofia Leora; Jun Wu; Shuya Hu; Keqiang Zhang; Mei-Ling Kuo; Lun Zhou; Hang Zhang; Yafan Wang; Yan Wang; Bingsen Zhou; Rebecca A Nelson; Shu Zheng; Suzhan Zhang; Peiguo Chu; Yun Yen
Journal:  Cancer Res       Date:  2011-03-17       Impact factor: 12.701

5.  E2F1 regulates p53R2 gene expression in p53-deficient cells.

Authors:  Jun-Juan Qi; Ling Liu; Ji-Xiang Cao; Guo-Shun An; Shu-Yan Li; Gang Li; Hong-Ti Jia; Ju-Hua Ni
Journal:  Mol Cell Biochem       Date:  2014-10-14       Impact factor: 3.396

Review 6.  Exploiting replicative stress to treat cancer.

Authors:  Matthias Dobbelstein; Claus Storgaard Sørensen
Journal:  Nat Rev Drug Discov       Date:  2015-05-08       Impact factor: 84.694

7.  dNTP pool levels modulate mutator phenotypes of error-prone DNA polymerase ε variants.

Authors:  Lindsey N Williams; Lisette Marjavaara; Gary M Knowels; Eric M Schultz; Edward J Fox; Andrei Chabes; Alan J Herr
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-31       Impact factor: 11.205

8.  Expression and maintenance of mitochondrial DNA: new insights into human disease pathology.

Authors:  Gerald S Shadel
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

9.  Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells.

Authors:  Giovanna Pontarin; Paola Ferraro; Leonardo Bee; Peter Reichard; Vera Bianchi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-30       Impact factor: 11.205

10.  Automated mass action model space generation and analysis methods for two-reactant combinatorially complex equilibriums: an analysis of ATP-induced ribonucleotide reductase R1 hexamerization data.

Authors:  Tomas Radivoyevitch
Journal:  Biol Direct       Date:  2009-12-09       Impact factor: 4.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.